These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 19177585)

  • 21. [How to obtain the most effective results when treating chronic hepatitis C virus?].
    Ouzan D
    Gastroenterol Clin Biol; 2007; 31(6-7):573-7. PubMed ID: 17646783
    [No Abstract]   [Full Text] [Related]  

  • 22. Some concerns about "PDCD1 and IFNL4 genetic variants and risk of developing hepatitis C virus-related diseases".
    Liu Y
    Liver Int; 2021 May; 41(5):1154. PubMed ID: 33058503
    [No Abstract]   [Full Text] [Related]  

  • 23. Letter: Response-guided treatment of hepatitis C virus genotype 5 may be feasible.
    Papastergiou V; Karatapanis S
    Aliment Pharmacol Ther; 2014 Jun; 39(11):1337-8. PubMed ID: 24803251
    [No Abstract]   [Full Text] [Related]  

  • 24. Letter: Response-guided treatment of hepatitis C virus genotype 5 may be feasible--authors' reply.
    Wantuck JM; Nguyen MH
    Aliment Pharmacol Ther; 2014 Jun; 39(11):1338. PubMed ID: 24803252
    [No Abstract]   [Full Text] [Related]  

  • 25. Rapid virological response in hepatitis C virus genotype 1 and early ribavirin exposure.
    Dai CY; Chuang WL; Huang JF; Hsieh MY; Yu ML
    Hepatology; 2008 Aug; 48(2):692-3; author reply 693-4. PubMed ID: 18666250
    [No Abstract]   [Full Text] [Related]  

  • 26. Ribavirin in chronic hepatitis C: past and future.
    Loustaud-Ratti V; Rousseau A; Marquet P; Denis F; Alain S
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):249-53. PubMed ID: 19344238
    [No Abstract]   [Full Text] [Related]  

  • 27. Treatment of patients infected with chronic hepatitis C genotype 2 and 3: more data, more questions?
    Graziadei IW; Vogel W
    Hepatology; 2009 Feb; 49(2):345-7. PubMed ID: 19177579
    [No Abstract]   [Full Text] [Related]  

  • 28. The optimal ribavirin dose for patients infected with hepatitis C virus genotype 3: should we utilize more?
    Aghemo A; Rumi MG; Prati GM; Colombo M
    Hepatology; 2009 Feb; 49(2):702-3; author reply 703-4. PubMed ID: 19177585
    [No Abstract]   [Full Text] [Related]  

  • 29. Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C.
    Morello J; Rodríguez-Novoa S; Jiménez-Nácher I; Soriano V
    J Antimicrob Chemother; 2008 Dec; 62(6):1174-80. PubMed ID: 18931138
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How to use virological tools for optimal management of chronic hepatitis C.
    Chevaliez S; Pawlotsky JM
    Liver Int; 2009 Jan; 29 Suppl 1():9-14. PubMed ID: 19207960
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of thyroid diseases in the treatment of chronic hepatitis C with alpha-interferon may be a good prognosticator in achieving a sustained virological response: a meta-analysis.
    Tran HA; Malcolm Reeves GE; Gibson R; Attia JR
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1163-8. PubMed ID: 19682190
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 33.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.